论文部分内容阅读
目的观察止嗽散联合布地奈德福莫特罗治疗咳嗽变异性哮喘(CVA)的临床疗效。方法将50例CVA患者随机分为对照组和治疗组,每组25例;对照组予布地奈德福莫特罗吸入治疗,治疗组在对照组基础上口服止嗽散,疗程4周。观察两组主要症状和肺功能变化情况。结果治疗后,两组咳嗽咳痰等症状积分和总积分均较治疗前明显降低(P<0.05),且治疗组低于对照组(P<0.05);治疗后两组肺功能[第1秒用力呼气容积(FEV_1)、呼气峰流速占预计值的百分比(PEF)]的变化情况较治疗前明显改善(P<0.05),且治疗组优于对照组(P<0.05)。结论止嗽散联合布地奈德福莫特罗吸入可改善CVA患者临床症状和肺功能。
Objective To observe the clinical curative effect of cough powder combined with budesonide formoterol on cough variant asthma (CVA). Methods Fifty patients with CVA were randomly divided into control group and treatment group, with 25 cases in each group. The control group was treated with budesonide formoterol inhalation. The treatment group was given CZT for 4 weeks on the basis of the control group. The main symptoms and changes of pulmonary function in two groups were observed. Results After treatment, the scores of cough and sputum in both groups were significantly lower than those before treatment (P <0.05), and were lower in the treatment group than those in the control group (P <0.05). After treatment, the pulmonary function [first second The forced expiratory volume (FEV_1) and the percentage of peak expiratory flow (PEF) were significantly improved compared with those before treatment (P <0.05), and the treatment group was better than the control group (P <0.05). Conclusion Zhisowan combined with budesonide formoterol inhalation can improve clinical symptoms and pulmonary function in patients with CVA.